Wednesday, July 8, 2020

Levilimab, a novel Monoclonal Anti-IL-6 Receptor Antibody, at the 2020 EULAR Online Meeting


Levilimab is novel monoclonal anti-IL-6 receptor antibody. As tocilizumab and sarilumab are already approved drugs in rheumatology, and olokizumab [1] has been presented at the 2020 EULAR Online Meeting in a phase 3 study, I'm suprised seeing another actor on the IL-6 stage. And there are still others like monoclonal anti-il-6 receptor antibodies: clazakinumab, elsilimomab, sirukumab; and more in oncology like siltuximab.

V. Mazurov and colleagues presented 1-year results of the phase 2 AURORA study [2]. AURORA assessed efficacy and safety of two dosing regimens of levilimab in patients with active rheumatoid arthritis and inadequate response to methotrexate (primary endpoint). Secondary endpoints mentioned: ACR20/50/70, LDA, remission rates, and DAS28-CRP(4); more data collected. Levilimab plus MTX showed sustained efficacy with continuous clinical improvement. The safety profile of levilimab was consistent with other IL-6 receptor inhibitors.

Do we need more IL-6-Inhibitors? Levilimab, clazakinumab, elsilimomab, sirukumab as well as the established tocilizumab, sarilumab, and siltuximab? I guess no, but that's the luxury of a free market economy.


Links and References:
[2] V. Mazurov1, E. Zotkin2, E. Ilivanova3, T. Kropotina4, T. Plaksina5, O. Nesmeyanova6, N. Soroka7, A. Kundzer8, A. Lutskii9, E. Dokukina9, A. Eremeeva9, A. Zinkina-Orihan9. FRI0114 EFFICACY OF LEVILIMAB, NOVEL MONOCLONAL ANTI-IL-6 RECEPTOR ANTIBODY, IN COMBINATION WITH METHOTREXATE IN PATIENTS WITH RHEUMATOID ARTHRITIS: 1-YEAR RESULTS OF PHASE 2 AURORA STUDY. DOI: 10.1136/annrheumdis-2020-eular.5465

.


No comments:

Post a Comment